Okyo Pharma has decided to delist its shares from the London Stock Exchange and list them on the Nasdaq in New York, blaming “negligible” trading that doesn’t justify the
Otonomy has chalked up its second clinical trial failure in the space of a few months, the latest in a mid-stage study of a treatment for hearing loss, and the biotech has now been forced i
AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho